Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early-stage HER2-positive breast cancer

First-line bevacizumab plus chemotherapy and cetuximab plus chemotherapy provide similar survival benefit for patients with metastatic colorectal cancer

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

Adjuvant exemestane more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer

Adjuvant exemestane is more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer

Comment: Advances in lung cancer presented at ASCO 2014

Comment: Advances in breast cancer presented at ASCO 2014

Ramucirumab plus docetaxel extends survival in advanced NSCLC

Targeted drug combo, cediranib plus olaparib, significantly increases progression-free survival in recurrent ovarian cancer

Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

Lenvatinib yields high response rates and delays progression in radioiodine-resistant, advanced differentiated thyroid cancer

Second-line treatment with ramucirumab plus docetaxel extends survival in advanced NSCLC